Entity

Time filter

Source Type

Gent, Belgium

Innogenetics N.V. is an international in vitro diagnostics company, with headquarters in Ghent, Belgium. The company develops and markets IVD testing solutions from specialized manual testing to fully automated routine testing that cover areas such as infectious diseases, oncology, genetic testing, thyroid, fertility, tissue typing, neurodegeneration and bone. The company was acquired in September 2010 by Japanese Fujirebio Inc., part of Miraca Holdings Inc., and changed name to Fujirebio Europe on October 1st 2013. The CEO of Fujirebio Europe N.V. is Christiaan De Wilde. Wikipedia.


Murphy D.G.,Institute National Of Sante Publique Du Quebec | Sablon E.,Innogenetics | Sablon E.,Biocartis | Chamberland J.,Institute National Of Sante Publique Du Quebec | And 3 more authors.
Journal of Clinical Microbiology | Year: 2015

We report a new hepatitis C virus (HCV) genotype identified in patients originating from the Democratic Republic of Congo. The prototype QC69 virus is shown to be a new lineage distinct from genotypes 1 to 6. Three additional patients were also found to be infected by a virus from this lineage, confirming its circulation in humans. We propose that these viruses be classified into HCV genotype 7. Copyright © 2015, American Society for Microbiology. All Rights Reserved. Source


Patent
Roche Holding AG and Innogenetics | Date: 2013-03-06

The present invention relates to new nucleic acid sequences derived from the ITS (Internal Transcribed Spacer) region, between the 16S and 23S ribosomal ribonucleic acid (rRNA) or rRNA genes, to be used for the specific detection and/or identification of


Patent
Innogenetics | Date: 2011-12-09

The current invention relates to a previously unrecognized clade of HCV genotypes as well as to diagnostic, prophylactic and therapeutic applications of nucleic acids, proteins, and antibodies to said protein, derived of or based on the newly characterized hepatitis C viruses.


Patent
Roche Holding AG and Innogenetics | Date: 2013-03-07

The present invention relates to new nucleic acid sequences derived from the ITS (Internal Transcribed Spacer) region, between the 16S and 23S rRNA genes, to be used for the specific detection and/or identification of


Patent
Innogenetics | Date: 2012-07-19

New polymorphisms in the nucleic acid sequences of the DNA polymerase/reverse transcriptase open reading frame and viral surface antigen open reading frame of the hepatitis B virus are reported. In particular, the present invention relates to the mutation YMDDYSDD in the HBV reverse transcriptase domain and to the W196V mutation in the small HBV viral surface antigen. Said polymorphisms are affecting the detection of drug resistance mutations by genotypic methods and diagnostic kits based thereon. The present invention relates to methods and diagnostic kits for detection of a HBV virus comprising said nucleic acid polymorphisms. In particular, those methods utilizing oligonucleotides capable of hybridizing to said HBV nucleic acid polymorphisms are envisaged.

Discover hidden collaborations